Adamas Pharmaceuticals, Inc. (ADMS)
(Delayed Data from NSDQ)
$6.39 USD
+0.11 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.38 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.39 USD
+0.11 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.38 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adamas (ADMS) delivered earnings and revenue surprises of 0.00% and -1.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Adamas Pharmaceuticals (ADMS) stock based on the movements in the options market lately.
Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adamas (ADMS) delivered earnings and revenue surprises of 25.00% and -1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?
by Zacks Equity Research
Cigna (CI) Q1 results are likely to reflect better revenues but a weak bottom line.
What's in Store for Select Medical (SEM) Earnings in Q1?
by Zacks Equity Research
Select Medical (SEM) Q1 results are likely to reflect improvement in patient volumes.
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Adamas (ADMS): Can Its 5.9% Jump Turn into More Strength?
by Zacks Equity Research
Adamas (ADMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adamas (ADMS) delivered earnings and revenue surprises of -20.76% and 1.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adamas (ADMS) delivered earnings and revenue surprises of 16.00% and -5.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Adamas Pharmaceuticals (ADMS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns
Nutanix (NTNX) to Post Q3 Earnings: What Lies in Store?
by Zacks Equity Research
Nutanix's (NTNX) third-quarter fiscal 2020 results are likely to have benefited from demand for its hybrid cloud solutions.
Intuit (INTU) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Intuit's (INTU) fiscal Q3 earnings are likely to have gained from buoyant demand for Quickbooks Online. However, an extension on tax filing deadline is likely to have weighed on the top line.
Palo Alto (PANW) to Report Q3 Earnings: What Lies in Store?
by Zacks Equity Research
Palo Alto's (PANW) third-quarter fiscal 2020 earnings are likely to have gained from the strong adoption of Prisma and Cortex platforms.
NortonLifeLock (NLOK) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
NortonLifeLock's (NLOK) Q4 results are likely to reflect growth in bookings. However, high tax payments are likely to have put cash flow under pressure.
Mallinckrodt (MNK) Q1 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.
EchoStar (SATS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Impact of higher churn rate with decline in enterprise services are likely to get reflected on EchoStar's (SATS) first-quarter 2020 results.
A10 Networks (ATEN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
A10 Networks' (ATEN) first-quarter 2020 performance is likely to have benefited from business optimization and a strong product line.
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Adamas (ADMS) Rating Upgrade to Buy
by Zacks Equity Research
Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
by Zacks Equity Research
Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.
Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adamas (ADMS) delivered earnings and revenue surprises of 6.74% and 0.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?